Stock Track | Kymera Therapeutics Plunges on Q3 Revenue Miss and Strategic Pivot

Stock Track

Nov 01, 2024

Shares of Kymera Therapeutics, Inc. (NASDAQ: KYMR) plummeted by 7.9% on October 31, 2024, as the biopharmaceutical company reported disappointing third-quarter financial results and announced a strategic shift in its business focus.

The company's quarterly revenue of $3.74 million missed analyst consensus estimates of $10.36 million by a staggering 63.9%, representing a 20.9% year-over-year decline. This significant revenue miss sent shockwaves through the market, with investors reacting negatively to the weaker-than-expected performance.

While Kymera beat earnings estimates, reporting a loss of $0.82 per share compared to the expected $0.84, the company's strategic pivot also weighed on investor sentiment. Kymera announced plans to shift its focus and resources from oncology to its expanding immunology pipeline, stating that it would only advance its two oncology candidates, KT-333 (STAT3) and KT-253 (MDM2), beyond Phase 1 with a partner. The company also selected a new immunology candidate, KT-295, a TYK2 degrader, to advance into a Phase 1 clinical trial in the first half of 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1181206915"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1181206915\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1181206915?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-01 06:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181206915","market":"hk","top_or_hot":-1,"title":"Stock Track | Kymera Therapeutics Plunges on Q3 Revenue Miss and Strategic Pivot","media":"Stock Track","content":"<p>Shares of Kymera Therapeutics, Inc. (NASDAQ: KYMR) plummeted by 7.9% on October 31, 2024, as the biopharmaceutical company reported disappointing third-quarter financial results and announced a strategic shift in its business focus.</p>\n\n<p>The company's quarterly revenue of $3.74 million missed analyst consensus estimates of $10.36 million by a staggering 63.9%, representing a 20.9% year-over-year decline. This significant revenue miss sent shockwaves through the market, with investors reacting negatively to the weaker-than-expected performance.</p>\n\n<p>While Kymera beat earnings estimates, reporting a loss of $0.82 per share compared to the expected $0.84, the company's strategic pivot also weighed on investor sentiment. Kymera announced plans to shift its focus and resources from oncology to its expanding immunology pipeline, stating that it would only advance its two oncology candidates, KT-333 (STAT3) and KT-253 (MDM2), beyond Phase 1 with a partner. The company also selected a new immunology candidate, KT-295, a TYK2 degrader, to advance into a Phase 1 clinical trial in the first half of 2025.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Kymera Therapeutics Plunges on Q3 Revenue Miss and Strategic Pivot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Kymera Therapeutics Plunges on Q3 Revenue Miss and Strategic Pivot\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-01 06:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Kymera Therapeutics, Inc. (NASDAQ: KYMR) plummeted by 7.9% on October 31, 2024, as the biopharmaceutical company reported disappointing third-quarter financial results and announced a strategic shift in its business focus.</p>\n\n<p>The company's quarterly revenue of $3.74 million missed analyst consensus estimates of $10.36 million by a staggering 63.9%, representing a 20.9% year-over-year decline. This significant revenue miss sent shockwaves through the market, with investors reacting negatively to the weaker-than-expected performance.</p>\n\n<p>While Kymera beat earnings estimates, reporting a loss of $0.82 per share compared to the expected $0.84, the company's strategic pivot also weighed on investor sentiment. Kymera announced plans to shift its focus and resources from oncology to its expanding immunology pipeline, stating that it would only advance its two oncology candidates, KT-333 (STAT3) and KT-253 (MDM2), beyond Phase 1 with a partner. The company also selected a new immunology candidate, KT-295, a TYK2 degrader, to advance into a Phase 1 clinical trial in the first half of 2025.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KYMR","symbol_name":"Kymera Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1181206915","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181206915","pubTimestamp":1730412762,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Kymera Therapeutics, Inc.  plummeted by 7.9% on October 31, 2024, as the biopharmaceutical company reported disappointing third-quarter financial results and announced a strategic shift in its business focus.The company's quarterly revenue of $3.74 million missed analyst consensus estimates of $10.36 million by a staggering 63.9%, representing a 20.9% year-over-year decline. This significant revenue miss sent shockwaves through the market, with investors reacting negatively to the weak","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KYMR":"Kymera Therapeutics, Inc."},"translate_title":"股票赛道Kymera Therapeutics因第三季度收入未达预期和战略转向而暴跌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KYMR":1},"content_text":"Shares of Kymera Therapeutics, Inc. (NASDAQ: KYMR) plummeted by 7.9% on October 31, 2024, as the biopharmaceutical company reported disappointing third-quarter financial results and announced a strategic shift in its business focus.\nThe company's quarterly revenue of $3.74 million missed analyst consensus estimates of $10.36 million by a staggering 63.9%, representing a 20.9% year-over-year decline. This significant revenue miss sent shockwaves through the market, with investors reacting negatively to the weaker-than-expected performance.\nWhile Kymera beat earnings estimates, reporting a loss of $0.82 per share compared to the expected $0.84, the company's strategic pivot also weighed on investor sentiment. Kymera announced plans to shift its focus and resources from oncology to its expanding immunology pipeline, stating that it would only advance its two oncology candidates, KT-333 (STAT3) and KT-253 (MDM2), beyond Phase 1 with a partner. The company also selected a new immunology candidate, KT-295, a TYK2 degrader, to advance into a Phase 1 clinical trial in the first half of 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}